You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

Authors

  • Patrick A Ott Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Matthew Nazzaro Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Kathleen L Pfaff Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Evisa Gjini Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Kristen D Felt Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jacquelyn O Wolff Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Elizabeth I Buchbinder Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Rizwan Haq Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Ryan J Sullivan Harvard Medical School, Boston, Massachusetts, USAMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Donald P Lawrence Harvard Medical School, Boston, Massachusetts, USAMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • David F McDermott Harvard Medical School, Boston, Massachusetts, USABeth Israel Deaconess Medical Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Mariano Severgnini Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Anita Giobbie-Hurder Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Scott J Rodig Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • F Stephen Hodi Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles

Citation

Ott PA, Nazzaro M, Pfaff KL, et al
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
Journal for ImmunoTherapy of Cancer 2021;9:e003318. doi: 10.1136/jitc-2021-003318
Online issue publication 
May 08, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.